Last reviewed · How we verify

BRII-198

National Institute of Allergy and Infectious Diseases (NIAID) · Phase 3 active Biologic

BRII-198 is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2) to enhance anti-tumor immune responses.

BRII-198 is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2) to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (Phase 3 development).

At a glance

Generic nameBRII-198
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Drug classPD-1 inhibitor
TargetPD-1
ModalityBiologic
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

BRII-198 is a humanized PD-1 inhibitor that prevents the engagement of programmed death receptor 1 (PD-1) on T cells with its ligands on tumor cells and immune cells. By blocking this inhibitory checkpoint, the drug restores T cell activation and proliferation, allowing the immune system to recognize and eliminate cancer cells. This mechanism is similar to other checkpoint inhibitors used in immuno-oncology.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results